Profile data is unavailable for this security.
About the company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
- Revenue in USD (TTM)251.23m
- Net income in USD48.58m
- Incorporated1987
- Employees68.00
- LocationLigand Pharmaceuticals Inc555 Heritage Drive,Suite 200JUPITER 33458United StatesUSA
- Phone+1 (858) 550-7500
- Fax+1 (302) 636-5454
- Websitehttps://www.ligand.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corp | 69.22m | -121.85m | 2.76bn | 157.00 | -- | 125.12 | -- | 39.94 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.86bn | 979.00 | -- | 6.27 | -- | 7.30 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 588.99m | 214.33m | 2.92bn | 182.00 | 14.20 | 3.07 | 11.58 | 4.96 | 1.68 | 1.68 | 4.63 | 7.79 | 0.6024 | 3.08 | 6.14 | 3,236,203.00 | 21.92 | 22.15 | 25.40 | 25.81 | 85.19 | 85.59 | 36.39 | 31.20 | 5.82 | -- | 0.00 | 0.00 | 19.78 | 37.68 | 30.78 | 23.37 | 38.45 | -- |
| Arcutis Biotherapeutics Inc | 376.07m | -16.14m | 2.93bn | 354.00 | -- | 15.36 | -- | 7.78 | -0.1325 | -0.1325 | 2.93 | 1.54 | 0.962 | 1.97 | 3.43 | 1,062,350.00 | -4.13 | -48.93 | -5.65 | -57.14 | 90.24 | -- | -4.29 | -147.21 | 2.99 | -3.84 | 0.3651 | -- | 91.34 | -- | 88.47 | -- | 101.59 | -- |
| Supernus Pharmaceuticals Inc | 718.95m | -38.55m | 3.14bn | 674.00 | -- | 2.95 | 59.14 | 4.37 | -0.6839 | -0.6839 | 12.70 | 18.48 | 0.5098 | 1.09 | 4.36 | -- | -2.73 | 2.01 | -3.52 | 2.67 | 89.63 | 87.96 | -5.36 | 4.66 | 1.66 | -- | -- | -- | 8.63 | 6.68 | -152.19 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 451.36m | -66.42m | 3.26bn | 370.00 | -- | 9.49 | -- | 7.22 | -1.61 | -1.61 | 10.81 | 8.07 | 0.9612 | 8.78 | 6.85 | 1,219,892.00 | -14.14 | -27.80 | -18.38 | -32.78 | 93.20 | 93.45 | -14.72 | -53.60 | 3.82 | -- | 0.1742 | -- | 146.71 | -- | 42.52 | -- | 84.92 | -- |
| Prestige Consumer Healthcare Inc | 1.10bn | 186.50m | 3.26bn | 600.00 | 18.25 | 1.78 | 15.07 | 2.96 | 3.78 | 3.78 | 22.38 | 38.66 | 0.3234 | 3.07 | 6.17 | 1,839,343.00 | 5.47 | 4.13 | 5.67 | 4.30 | 56.12 | 56.31 | 16.90 | 13.13 | 1.93 | 8.28 | 0.3657 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 677.56m | 59.01m | 3.47bn | 366.00 | 60.92 | 6.10 | 57.34 | 5.12 | 0.7448 | 0.7448 | 8.58 | 7.44 | 1.01 | 1.91 | 23.64 | 1,851,268.00 | 8.78 | 2.35 | 10.69 | 2.75 | 88.54 | 87.48 | 8.71 | 3.40 | 3.39 | -- | 0.00 | 0.00 | 60.09 | -- | 236.61 | -- | 40.84 | -- |
| Corcept Therapeutics Inc | 761.41m | 99.65m | 3.75bn | 730.00 | 42.49 | 5.77 | 37.23 | 4.93 | 0.8303 | 0.8303 | 6.35 | 6.11 | 0.908 | 1.03 | 13.39 | 1,043,023.00 | 11.88 | 17.68 | 14.54 | 20.76 | 98.30 | 98.47 | 13.09 | 20.88 | 2.85 | -- | 0.00 | 0.00 | 12.79 | 16.56 | -29.43 | -1.23 | -29.80 | -- |
| Indivior Pharmaceuticals, Inc | 1.18bn | 122.00m | 3.86bn | 1.03k | 32.18 | -- | 26.09 | 3.27 | 0.9592 | 0.9592 | 9.20 | -1.66 | 0.8194 | 1.03 | 4.63 | 1,145,631.00 | 8.68 | -1.36 | 26.23 | -2.98 | 85.51 | 84.87 | 10.59 | -2.47 | 0.7938 | 9.33 | 2.80 | -- | 8.69 | 8.64 | 101.55 | -56.87 | 34.66 | -- |
| ADMA Biologics Inc | 510.17m | 146.93m | 3.90bn | 647.00 | 27.32 | 8.16 | 25.16 | 7.65 | 0.5996 | 0.5996 | 2.08 | 2.01 | 0.9168 | 1.15 | 4.90 | 788,520.90 | 26.40 | 9.62 | 29.75 | 10.91 | 57.39 | 44.75 | 28.80 | 12.51 | 3.74 | 37.09 | 0.1313 | 0.00 | 19.63 | 64.60 | -25.67 | -- | 12.46 | -- |
| Ligand Pharmaceuticals Inc | 251.23m | 48.58m | 4.07bn | 68.00 | 98.29 | 4.23 | 49.19 | 16.21 | 2.08 | 2.08 | 12.77 | 48.34 | 0.2066 | 1.01 | 5.47 | 3,694,603.00 | 4.00 | 1.82 | 4.09 | 1.92 | 94.27 | 82.57 | 19.34 | 10.30 | 24.30 | -- | 0.3192 | 0.00 | 27.28 | 6.80 | -107.49 | -- | -6.53 | -- |
| Amneal Pharmaceuticals Inc | 3.02bn | 72.06m | 4.19bn | 8.50k | 59.49 | -- | 11.91 | 1.39 | 0.2237 | 0.2237 | 9.29 | -0.225 | 0.8409 | 3.13 | 3.61 | 355,148.30 | 3.56 | -1.24 | 5.09 | -1.61 | 36.88 | 36.59 | 4.24 | -1.83 | 1.48 | 1.70 | 0.9977 | -- | 8.05 | 8.66 | 161.65 | -- | 11.56 | -- |
| TG Therapeutics Inc | 616.29m | 447.18m | 4.61bn | 399.00 | 10.40 | 6.92 | 10.31 | 7.48 | 2.78 | 2.78 | 3.82 | 4.17 | 0.7511 | 0.8534 | 2.83 | 1,544,579.00 | 54.50 | -3.81 | 64.04 | -4.57 | 83.66 | 87.01 | 72.56 | -7.46 | 3.29 | 4.61 | 0.2749 | -- | 87.32 | 426.73 | 1,812.41 | -- | -9.73 | -- |
| Mirum Pharmaceuticals Inc | 521.31m | -23.36m | 5.30bn | 369.00 | -- | 14.48 | 6,013.61 | 10.16 | -0.4783 | -0.4783 | 10.07 | 6.06 | 0.6889 | 4.24 | 5.17 | 1,412,770.00 | -3.09 | -19.72 | -3.96 | -23.84 | 80.77 | 78.68 | -4.48 | -43.34 | 2.55 | -13.32 | 0.4961 | -- | 54.74 | -- | 73.43 | -- | 33.50 | -- |
| PTC Therapeutics, Inc. | 1.73bn | 682.64m | 5.33bn | 991.00 | 8.29 | -- | 7.39 | 3.08 | 7.77 | 7.77 | 20.73 | -2.52 | 0.7518 | 0.9143 | 10.18 | 1,746,372.00 | 29.66 | -14.19 | 44.70 | -19.65 | 97.28 | 94.76 | 39.44 | -29.50 | 2.27 | 5.24 | 1.09 | -- | 114.51 | 35.37 | 287.90 | -- | -13.07 | -- |
Data as of Mar 04 2026. Currency figures normalised to Ligand Pharmaceuticals Inc's reporting currency: US Dollar USD
48.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.68m | 13.61% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.92m | 9.75% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 917.05k | 4.66% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 751.21k | 3.82% |
| Nomura Investment Management Business Trustas of 31 Dec 2025 | 644.09k | 3.27% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 577.58k | 2.94% |
| Chicago Capital LLCas of 31 Dec 2025 | 561.42k | 2.85% |
| Massachusetts Financial Services Co.as of 31 Dec 2025 | 507.02k | 2.58% |
| Stephens Investment Management Group LLCas of 31 Dec 2025 | 502.70k | 2.55% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 495.69k | 2.52% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
